{
    "status": "ok",
    "totalResults": 14,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "benzinga.com",
            "title": "Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage",
            "description": "MALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. STIM, a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders,\u2026",
            "url": "https://biztoc.com/x/778441966818bde6",
            "urlToImage": "https://c.biztoc.com/p/778441966818bde6/s.webp",
            "publishedAt": "2023-11-09T13:52:08Z",
            "content": "MALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. STIM, a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality\u2026 [+316 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Coherent Market Insights Pvt. Ltd",
            "title": "Deep Brain Stimulation Devices Market to Hit $2,508.5 Million by 2030, Rising at 9.8% CAGR | Coherent Market Insights",
            "description": "Deep Brain Stimulation Devices Companies Analyzed are Boston Scientific Corporation, Medtronic, Inc., St. Jude Medical, Inc. (Abbott Laboratories), Cyberonics, Inc., Neuronetics, and Aleva Neurotherapeutics SA. Deep Brain Stimulation Devices Companies Analyze\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/10/2778327/0/en/Deep-Brain-Stimulation-Devices-Market-to-Hit-2-508-5-Million-by-2030-Rising-at-9-8-CAGR-Coherent-Market-Insights.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/450ec960-647a-4b12-8885-a4afd6739e88",
            "publishedAt": "2023-11-10T13:35:00Z",
            "content": "Burlingame, Nov. 10, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global\u00a0deep brain stimulation device market is estimated to be valued at US$ 1,188.9 million in 2022 and is expect\u2026 [+10539 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage",
            "description": "(marketscreener.com) Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered LivesMALVERN, Pa., Nov. 09, 2023 -- Neuronetics, Inc. , a commercial stage medical technology company focused on designing, developing, and mar\u2026",
            "url": "https://www.marketscreener.com/quote/stock/NEURONETICS-INC-44403632/news/Neuronetics-Announces-Continued-Momentum-from-Health-Plans-for-TMS-Therapy-Coverage-45287163/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-09T13:33:01Z",
            "content": "Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered Lives\r\nMALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial st\u2026 [+3542 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "NeuroStar TMS Receives Expanded Regulatory Approval in Japan",
            "description": "(marketscreener.com) Technological advances reduce time and increase efficiency for MDD treatmentMALVERN, Pa., Dec. 04, 2023 -- Neuronetics, Inc. , a medical technology company focused on designing, developing, and marketing products that improve the quality \u2026",
            "url": "https://www.marketscreener.com/quote/stock/NEURONETICS-INC-44403632/news/NeuroStar-TMS-Receives-Expanded-Regulatory-Approval-in-Japan-45494448/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-12-04T13:57:01Z",
            "content": "Technological advances reduce time and increase efficiency for MDD treatment\r\nMALVERN, Pa., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on\u2026 [+3876 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Neuronetics",
            "title": "Neuronetics Reports Third Quarter 2023 Financial and Operating Results",
            "description": "MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Neuronetics,\u00a0Inc. (NASDAQ: STIM) (the \u201cCompany\u201d or \u201cNeuronetics\u201d) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help,\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/07/2774966/0/en/Neuronetics-Reports-Third-Quarter-2023-Financial-and-Operating-Results.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/12db9039-d4bf-41a0-8b4a-324398e392b4",
            "publishedAt": "2023-11-07T12:30:00Z",
            "content": "MALVERN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Neuronetics,\u00a0Inc. (NASDAQ: STIM) (the Company or Neuronetics) a commercial stage medical technology company with a strategic vision of transforming the\u2026 [+31187 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Neuronetics",
            "title": "Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference",
            "description": "MALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today \u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/15/2781416/0/en/Neuronetics-to-Present-at-the-35th-Annual-Piper-Sandler-Healthcare-Conference.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/12db9039-d4bf-41a0-8b4a-324398e392b4",
            "publishedAt": "2023-11-15T21:15:00Z",
            "content": "MALVERN, Pa., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of lif\u2026 [+1833 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Neuronetics",
            "title": "Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage",
            "description": "Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered Lives Policy Updates from Magellan and Two Additional Payors Increase Access for 3.2 Million Covered Lives",
            "url": "https://www.globenewswire.com/news-release/2023/11/09/2777387/0/en/Neuronetics-Announces-Continued-Momentum-from-Health-Plans-for-TMS-Therapy-Coverage.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/12db9039-d4bf-41a0-8b4a-324398e392b4",
            "publishedAt": "2023-11-09T13:32:00Z",
            "content": "MALVERN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve t\u2026 [+3434 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Neuronetics",
            "title": "Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
            "description": "MALVERN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth \u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/06/2774567/0/en/Neuronetics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/12db9039-d4bf-41a0-8b4a-324398e392b4",
            "publishedAt": "2023-11-06T21:30:00Z",
            "content": "MALVERN, Pa., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve t\u2026 [+4967 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Greenbrook TMS Announces Settlement of Ongoing Litigation",
            "description": "(marketscreener.com) \n\nTORONTO, Nov. 21, 2023 /PRNewswire/ - Greenbrook TMS Inc. announced today that the Company has entered into a settlement agreement with the plaintiff regarding the previously-announced breach of contract claim in connection with an appr\u2026",
            "url": "https://www.marketscreener.com/quote/stock/GREENBROOK-TMS-INC-47342203/news/Greenbrook-TMS-Announces-Settlement-of-Ongoing-Litigation-45411441/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-21T22:01:03Z",
            "content": "TORONTO, Nov. 21, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) (\"Greenbrook\" or the \"Company\") announced today that the Company has entered into a settlement agreement with the plaintiff re\u2026 [+8412 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS",
            "description": "(marketscreener.com) \n\nPLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ --\u00a0Harmony Biosciences Holdings, Inc. , a pharmaceutical company dedicated to\u00a0developing and commercializing innovative therapies for patients with rare neurological diseases, today annou\u2026",
            "url": "https://www.marketscreener.com/quote/stock/HARMONY-BIOSCIENCES-HOLDI-111065683/news/HARMONY-BIOSCIENCES-APPOINTS-PETER-ANASTASIOU-TO-ITS-BOARD-OF-DIRECTORS-45272750/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-08T13:06:04Z",
            "content": "PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ --\u00a0Harmony Biosciences Holdings, Inc. (\"Harmony\" or the \"Company\") (Nasdaq: HRMY), a pharmaceutical company dedicated to\u00a0developing and commercializin\u2026 [+3034 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "GREENBROOK TMS RAISES US$2.5 MILLION IN DEBT FINANCING",
            "description": "(marketscreener.com) \n\nTORONTO, Nov. 16, 2023 /PRNewswire/ -\u00a0Greenbrook TMS Inc. today announced that it has entered into the nineteenth amendment to the Company's credit facility with affiliates of Madryn Asset Management, LP . As part of the Amendment, the \u2026",
            "url": "https://www.marketscreener.com/quote/stock/GREENBROOK-TMS-INC-47342203/news/GREENBROOK-TMS-RAISES-US-2-5-MILLION-IN-DEBT-FINANCING-45374602/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-16T14:16:05Z",
            "content": "TORONTO, Nov. 16, 2023 /PRNewswire/ -\u00a0Greenbrook TMS Inc. (NASDAQ: GBNH) (\"Greenbrook\" or the \"Company\") today announced that it has entered into the nineteenth amendment (the \"Amendment\") to the Com\u2026 [+9420 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "Vantage Market Research",
            "title": "Global Neuromodulation Market Size & Share to Surpass $14.8 Billion by 2030 | Vantage Market Research",
            "description": "WASHINGTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- According to Vantage Market Research, the Global Neuromodulation Market is estimated to be valued at USD 14.8 Billion by 2030 at an exponential growth of 12.2% in the next seven years.",
            "url": "https://www.globenewswire.com/news-release/2023/11/22/2784936/0/en/Global-Neuromodulation-Market-Size-Share-to-Surpass-14-8-Billion-by-2030-Vantage-Market-Research.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/b992ad70-52a5-4308-9ec3-ec32ebfecaee",
            "publishedAt": "2023-11-22T16:15:00Z",
            "content": "WASHINGTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- According to Vantage Market Research, the Global Neuromodulation Market is estimated to be valued at USD 14.8 Billion by 2030 at an exponential growth of\u2026 [+12165 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED",
            "title": "Neurostimulation Market projected to reach USD 9.9 Billion by 2030, growing at a CAGR of 9.3% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study",
            "description": "The Global Neurostimulation Market was valued USD 5.3 Billion in 2023 and projected to reach USD 9.9 Billion by 2030, growing at a CAGR of 9.3% during the forecast period of 2023-2030. The Global Neurostimulation Market was valued USD 5.3 Billion in 2023 and \u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/21/2784174/0/en/Neurostimulation-Market-projected-to-reach-USD-9-9-Billion-by-2030-growing-at-a-CAGR-of-9-3-during-the-forecast-period-of-2023-2030-pronounced-by-MarketDigits-in-its-recent-study.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/2960b872-d623-4363-9973-e881f17bf42f",
            "publishedAt": "2023-11-21T15:00:00Z",
            "content": "Richmond, Nov. 21, 2023 (GLOBE NEWSWIRE) -- According to a research report \"Neurostimulation Market\r\n, byType (Internal Neurostimulation (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve\u2026 [+11190 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Plos.org"
            },
            "author": "Ane Miren Guti\u00e9rrez-Muto, Sven Bestmann, Rub\u00e9n S\u00e1nchez de la Torre, Jos\u00e9 L. Pons, Antonio Oliviero, Jes\u00fas Tornero",
            "title": "The complex landscape of TMS devices: A brief overview",
            "description": "The increasing application of TMS in research and therapy has spawned an ever-growing number of commercial and non-commercial TMS devices and technology development. New CE-marked devices appear at a rate of approximately one every two years, with new FDA-app\u2026",
            "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0292733",
            "urlToImage": "https://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0292733.g004&size=inline",
            "publishedAt": "2023-11-28T14:00:00Z",
            "content": "Abstract\r\nThe increasing application of TMS in research and therapy has spawned an ever-growing number of commercial and non-commercial TMS devices and technology development. New CE-marked devices a\u2026 [+54992 chars]"
        }
    ]
}